Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.
The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope.
Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.
Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need.
The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $337M
Founded date: 2019
Investors 3
Date | Name | Website |
- | 8VC | 8vc.com |
27.10.2020 | Eclipse Ve... | eclipse.vc |
- | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 2
Date | Series | Amount | Investors |
23.08.2023 | Series C | $255M | - |
05.05.2021 | Series B | $82M | Eclipse Ve... |
Mentions in press and media 19
Date | Title | Description |
01.05.2024 | Xtalks Announces its Life Science Webinar Calendar for May 2024 | https://www.xtalks.com Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, food, healthcare, laboratory technology, m... |
15.04.2024 | Fully Automated cGMP Cell Therapy Manufacturing on Cellares' Cell Shuttle Platform, Upcoming Webinar Hosted by Xtalks | www.cellares.com In this free webinar, gain insights into a novel approach that can be useful for large-scale cell therapy manufacturing. Attendees will learn about Cellares' global network of Current Good Manufacturing Practice (cGMP) Inte... |
23.08.2023 | Cellares Lands $255M Series C | SOUTH SAN FRANCISCO, CA, Cellares, dedicated to clinical and industrial-scale cell therapy manufacturing, announced a $255 million Series C funding round. >> Click here for more funding data on Cellares >> To export Cellares... |
23.08.2023 | Cellares Raises $255M in Series C Funding | Cellares, a South San Francisco, CA-based integrated development and manufacturing organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, raised $255M in Series C funding. The round was led by Koch Disrup... |
14.12.2021 | Cellares Finishes Year of Strong Growth With Key Hires | SOUTH SAN FRANCISCO, Calif., Dec. 14, 2021 /PRNewswire/ -- Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced several new additions to its le... |
19.11.2021 | Takeda oncology vet drills down the 'basics' at cell therapy startup; Sarepta promotes new R&D chief | Kathryn Corzo Kathryn Corzo — an oncology veteran and the program head behind Sanofi’s multiple myeloma monoclonal antibody isatuximab — is now in the C-suite. The newest member at cell therapy player bit.bio as their... |
05.06.2021 | Cellares Secures $82M to Automate Cell Therapy Manufacturing | - |
06.05.2021 | Cellares Raises $82M in Series B | SOUTH SAN FRANCISCO, CA, Cellares has secured $82 million in a Series B round co-led by Decheng Capital and Eclipse Ventures. >> Click here for more funding data on Cellares >> To export Cellares funding data to PDF and Exce... |
05.05.2021 | Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing USA - English USA - English | |
05.05.2021 | Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing | SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, today announced it has secured $82 million in a Series B round, bringing total fund... |
Show more